Listed

Arbutus Biopharma Corp: Form 10-K for the period ended Dec 31, 2021

Filed with the SEC on Mar 3, 2022 and accepted by EDGAR at Mar 3, 2022, 16:43 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2021-01-01 to 2021-12-31$11.0mus-gaap:Revenues
Research and development12 months2021-01-01 to 2021-12-31$65.5mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2021-01-01 to 2021-12-31−$73.5mus-gaap:OperatingIncomeLoss
Interest expense12 months2021-01-01 to 2021-12-31$2.9mus-gaap:InterestExpense
Income tax12 months2021-01-01 to 2021-12-31$0us-gaap:IncomeTaxExpenseBenefit
Net income12 months2021-01-01 to 2021-12-31−$76.2mus-gaap:NetIncomeLoss
Diluted EPS12 months2021-01-01 to 2021-12-31−$0.83us-gaap:EarningsPerShareDiluted
Basic EPS12 months2021-01-01 to 2021-12-31−$0.83us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2021-01-01 to 2021-12-31106,242,452 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2021-01-01 to 2021-12-31−$67.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2021-01-01 to 2021-12-31$809.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-12-31$109.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-12-31$160.7mus-gaap:AssetsCurrent
Total assetsAt period end2021-12-31$204.5mus-gaap:Assets
Current liabilitiesAt period end2021-12-31$11.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-12-31$35.0mus-gaap:Liabilities
Long-term debtAt period end2021-12-31$0us-gaap:LongTermDebt
Shareholders' equityAt period end2021-12-31$169.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001447028-22-000019. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.